Cerebral cortical Aβ42 and PHF-τ in 325 consecutive brain autopsies stratified by diagnosis, location, and APOE

Journal of Neuropathology and Experimental Neurology

Volumn 74, Issue 2, 2015, Pages 100-109

  Postupna, Nadia ^a   Keene, Christopher Dirk ^a   Crane, Paul K ^a   Gonzalez Cuyar, Luis F ^a   Sonnen, Joshua A ^a   Hewitt, Jessica ^a   Rice, Samantha ^a   Howard, Kimberly ^a   Montine, Kathleen S ^b   Larson, Eric B ^c   Montine, Thomas J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloid ; Apolipoprotein E; Neurodegeneration; Neuropathology, Paired helical filament

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; APOLIPOPROTEIN E4; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN CORTEX; BRAIN INJURY; BRAIN TISSUE; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DIAGNOSIS RELATED GROUP; DIFFUSE LEWY BODY DISEASE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; PAIRED HELICAL FILAMENT; PARIETAL CORTEX; PRIORITY JOURNAL; TEMPORAL CORTEX; AGED; ANALYSIS OF VARIANCE; FEMALE; GENETICS; GENOTYPE; HEALTH CARE PLANNING; MALE; METABOLISM; PATHOLOGY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; APOLIPOPROTEIN E4; AUTOPSY; CEREBRAL CORTEX; COMMUNITY HEALTH PLANNING; DEMENTIA; FEMALE; GENOTYPE; HUMANS; MALE; PEPTIDE FRAGMENTS; SEVERITY OF ILLNESS INDEX; TAU PROTEINS;

EID: 84921915458     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000153     Document Type: Article

References (36)

1. Beecham GW, Hamilton K, Naj AC, et al. Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias. PLoS Genet 2014;10:e1004606
2. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370: 322-33
3. Postupna N, Rose SE, Bird TD, et al. Novel antibody capture assay for paraffin-embedded tissue detects wide-ranging amyloid beta and paired helical filament-tau accumulation in cognitively normal older adults. Brain Pathol 2012;22:472-84
4. Teng EL, Hasegawa K, Homma A, et al. The Cognitive Abilities Screening Instrument (CASI): A practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr 1994;6:45-58; discussion 62
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association, 1994
6. Larson EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 2006;144:73-81
7. Barnhart RL, van Belle G, Edland SD, et al. Geographically overlapping Alzheimer's disease registries: Comparisons and implications. J Geriatr Psychiatry Neurol 1995;8:203-8.
8. Tsuang D, Simpson KL, Li G, et al. Evaluation of selection bias in an incident-based dementia autopsy case series. Alzheimer Dis Assoc Disord 2005;19:67-73
9. Haneuse S, Schildcrout J, Crane P, et al. Adjustment for selection bias in observational studies with application to the analysis of autopsy data. Neuroepidemiology 2009;32:229-39
10. Sonnen JA, Larson EB, Crane PK, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 2007;62:406-13
11. Sonnen JA, Santa Cruz K, Hemmy LS, et al. Ecology of the aging human brain. Arch Neurol 2011;68:1049-56
12. Tsuang D, Larson EB, Li G, et al. Association between lifetime cigarette smoking and Lewy body accumulation. Brain Pathol 2010;20:412-18
13. Sonnen JA, Larson EB, Gray SL, et al. Free radical damage to cerebral cortex in Alzheimer's disease, microvascular brain injury, and smoking. Ann Neurol 2009a;65:226-29
14. Sonnen JA, Larson EB, Brickell K, et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 2009b;66: 315-22
15. Sonnen JA, Larson EB, Walker RL, et al. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology 2010;75: 1203-10
16. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31: 545-48
17. Emi M, Wu LL, Robertson MA, et al. Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics 1988;3:373-79
18. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41:479-86
19. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
20. Hyman BT, Phelps CH, Beach TG, et al. National Institute on AgingYAlzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012;8:1-13
21. Montine TJ, Phelps CH, Beach TG, et al. National Institute on AgingYAlzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol 2012;123:1-11
22. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207-16
23. Yang W, Woltjer RL, Sokal I, et al. Quantitative proteomics identifies surfactant-resistant alpha-synuclein in cerebral cortex of Parkinsonism-dementia complex of Guam but not Alzheimer's disease or progressive supranuclear palsy. Am J Pathol 2007;171: 993-1002
24. Risacher SL, Kim S, Shen L, et al. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci 2013;5:11
25. Okamura N, Furumoto S, Fodero-Tavoletti MT, et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain 2014;137:1762-71
26. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013;79:1094-108
27. Chetelat G, Fouquet M. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers. Rev Neurol (Paris) 2013;169: 729-36
28. Scheinin NM, Wikman K, Jula A, et al. Cortical (1)(1)C-PIB uptake is associated with age, APOE genotype, and gender in "healthy aging". J Alzheimers Dis 2014;41:193-202
29. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2009;106:6820-25
30. Yu L, Boyle PA, Leurgans S, et al. Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. Neurobiol Aging 2014;35:819-26
31. Arvanitakis Z, Leurgans SE, Barnes LL, et al. Microinfarct pathology, dementia, and cognitive systems. Stroke 2011;42:722-27
32. Schneider JA, Arvanitakis Z, Yu L, et al. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain 2012;135:3005-14
33. Gelber RP, Launer LJ, White LR. The Honolulu-Asia Aging Study: Epidemiologic and neuropathologic research on cognitive impairment. Curr Alzheimer Res 2012;9:664-72
34. Richardson K, Stephan BC, Ince PG, et al. The neuropathology of vascular disease in the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Curr Alzheimer Res 2012;9:687-96
35. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000;283:1571-77
36. Woltjer RL, Sonnen JA, Sokal I, et al. Quantitation and mapping of cerebral detergent-insoluble proteins in the elderly. Brain Pathol 2009;19:365-74